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The chalcone-like series 1a–1g was efﬁciently synthesized from Morita–Baylis–Hillman reaction
(52–74% yields). Compounds 1a–1g were designed by molecular hybridization based on the anti-inﬂam-
matory drug methyl salicylate (3) and the antileishmanial moiety of the Morita–Baylis–Hillman adducts
2a–2g. The 1a–1g compounds were much more actives than precursor series 2a–2g, for example,
IC50 = 7.65 lM on Leishmania amazonensis and 10.14 lM on Leishmania chagasi (compound 1c) when
compared to IC50 = 50.08 lM on L. amazonensis and 82.29 lM on L. chagasi (compound 2c). The IC50 val-
ues of compound 3 (228.49 lM on L. amazonensis and 261.45 lM on L. chagasi) and acryloyl salicylate 4
(108.50 lM on L. amazonensis and 118.83 lM on L. chagasi) were determined here, by the ﬁrst time, on
Leishmania.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Leishmaniasis affects almost 12 million people in nearly 90
countries, representing a worldwide public health problem. More
than350millionpeople are currently at risk, and2millionnewcases
are registered each year. An estimated 51,000 annual deaths for
leishmaniasis have been reported.1–3 Leishmaniasis infection causes
manydifferent clinicalmanifestations, such as cutaneous,4mucocu-
taneous5 and a fatal infection of the liver and spleen (visceral
leishmaniasis, also known as kalazar).6,7 Human infection with
Leishmania chagasi, the protozoan causing South American visceral
leishmaniasis (VL), causes diverse sequelae ranging from subclinical
infection to progressive fatal disease.8 However, the cutaneous form
is themost common. Both the cutaneous andmucocutaneous forms
can cause severe disﬁgurement to patients, includingulcerative skin
lesions and the destruction of the mucous membranes of the nose,
mouth, and throat, leading to permanent disﬁgurement (diffuse
cutaneous form of the disease) and frequently social ostracization.
The most common species in the Americas and the most important
causative agent of cutaneous and mucocutaneous leishmaniasis in
Brazil is Leishmania braziliensis, while Leishmania amazonensis isax: +55 083 3216 7333.
asconcellos).
Elsevier OA license.the primary etiologic agent of the diffuse cutaneous form of the
disease.9
For the last 60 years, the treatment options for leishmaniasis
are limited and involve the administration pentavalent antimonial
family agents, represented by Sodium stibogluconate (Pentostam)
and Meglumine antimoniate (Glucantime). Second line drugs in-
clude pentamidine and Amphotericin B, but these drugs have not
experienced widespread use due to the severe toxicities and high
costs.10 Pentamidine present several side effects, including renal
and hepatic toxicity, pancreatitis, hypotension, dysglycemia, and
cardiac abnormalities.11 Amphotericin B is quite effective for vis-
ceral leishmaniasis being, however very expensive and do not ap-
pear to be suitable for treatment of non-visceral diseases.11 Up to
now, no vaccine approved for human use is available.12,13 There-
fore, there is an increasingly urgent need for the development of
new, inexpensive, effective and safe drugs for the treatment of
leishmaniasis and then, the discovery of new lead compounds for
this disease is a pressing concern for global health programs.
A promising route towards development of improved therapeu-
tic agents for diseases caused by human pathogens, such as para-
sitic protozoa, is the identiﬁcation of key differences between the
metabolism of the host and the parasite, and the development of
inhibitors of parasite-speciﬁc enzymes.14 The mechanisms by
which different Leishmania species cause different pathologies
are largely unknown. In a pioneering paper on this subject, Baiocco
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Figure 1. Previous antileishmanial compounds 2a–2g, a new hybrid series of
chalcone-like compounds synthesized here 1a–1g, methyl salicylate 3, and a new
compound acryloyl salicylate 4.
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Scheme 1. The Morita–Baylis–Hillman reaction (MBHR).
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of antimonial drugs against the parasite Sb(III), which is coordi-
nated by the two redox-active catalytic cysteine residues (Cys52
and Cys57), one threonine residue (Thr335), and His4610 of the
2-fold symmetry related subunit in the dimer, strongly inhibits try-
panothione reductase (TR).
Non-steroid anti-inﬂammatory drug NSAIDs are major drugs
used in the treatment of inﬂammation and pain in a wide variety
of disorders.16 NSAIDs constitute a diverse group of chemicals, cat-
egorized according to their chemical structures that share the same
therapeutic properties. Among themain compounds are aspirin and
salicylate, diclofenac and ﬂurbiprofen. The best-knownmechanism
of action of NSAIDs is the inhibition of prostaglandin synthesis sec-
ondary to their action on cyclooxygenases (COXs). However, data
have been accumulating through the years indicating that NSAIDs
also act on other targets to counteract pain17,18 Since anti-inﬂam-
matory activities of natural19 and non-natural20 salicylate deriva-
tives have been described and there is an important roles of COXs
and PGE2 during Leishmaniasis infection,21 the design of the new
hybrid salicylate compounds 1a–1g (Fig. 1) could be an attractive
strategy for discover new antileishmania substances.
In our continuing search for bioactive substances22–26 and in
connection with our efforts towards reactivity of Morita–
Baylis–Hillman reaction (MBHR) study (Scheme 1),27–30 our
research group described in 2006 the molluscicidal activities of
simple aromatic Morita–Baylis–Hillman adducts (MBHA) against
Biomphalaria glabrata (Say) snails, intermediate schistosomiasis
host.31 In sequence, some aromatic MBHA were presented as very
active compounds against the L. amazonensis (cutaneous and
mucocutaneous infections).32 Following that work, we published
the biological evaluation of aromatic MBHA against L. chagasi
(visceral infections) parasites,33 and in 2010, we have shown that
the MBHA 3-hydroxy-2-methylene-3-(4-nitrophenyl) propaneni-
trile, a high antileishmania compound, is also a highly active
compound against epimastigote and trypomastigote form of
Trypanosoma cruzi, the parasite that causes Chagas disease.34 In
the same year, we presented an improved synthesis for 16 MBHA
and their biological evaluation against L. amazonensis and L. chagasi
and we proposed, at the ﬁrst time, a Structure–Activity-Relation-
ship (SAR) analysis for this class of new antiparasitic compounds.35
In this context, we present in this Letter the design, synthesis,
inhibitory activities on antipromastigote form of L. amazonensis
and L. chagasi of new congener hybrids 1a–1g (Fig. 1). The design
is based on the molecular hybridization36 between the antileish-
mania compounds 2a–2g presented by us in previous paper35
and the methyl salicylate (3) (Fig. 1) (e.g., Metedic). It is important
to detach that the molecular hybridization is a relatively new con-
cept in drug design and development based on the combination of
pharmacophoric moieties of different bioactive substances to pro-
duce a new hybrid compound with improved bioactivity, when
compared to the parent compounds.36
Methylsalicylate (MS) is a naturally occurring compound that
is used as a major active ingredient of balms and liniments sup-
plied as topical analgesics. Despite the common use of MS as a
pain reliever, the underlying molecular mechanism is not fully
understood. Recently, Ohta et al. showed that the inhibitory ac-
tion of MS on transient receptor potential vanilloid subtype 1
(TRPV1) is one of the underlying mechanisms for its analgesic ef-
fects in vivo.37
In this Letter we also present, by the ﬁrst time, the toxicity eval-
uation against promastigotes forms of L. amazonensis and L. chagasi
of methyl salicylate (3) and the acryloyl salicylate (4) (Fig. 1). All
molecular hybridsMBHAdesignedhere are in accordwith the Lipin-
ski’s rule of ﬁve38 and also with the recent Reynisson’s rule.39
We also should emphasize the structural similarity between
compounds 1a–1g designed here and the chalcones (Scheme 2)that exhibit various biological activities, such as antibacterial,
antifungal, antitumor, anti-inﬂammatory and antiparasitic
properties.40–42 Several chalcone-like compounds have been
recently synthesized and also exhibit various biological activities.43
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2.1. Chemistry
Commercially available reagents were purchased from Aldrich
and Acros and used without further puriﬁcation. The solvents
used in this study were purchased from Tedia, the acryloyl chlo-
ride was purchased from Merck and methyl salicylate was pur-
chased from Dynamics. All the new compounds were
characterized by 1H NMR, 13C NMR, FT-IR, and HR-MS, using a
NMR Varian Unitty Plus (300 MHz to 1H and 75 MHz for 13C), a
NMR Varian Unmrs (400 MHz 1H and 100 MHz for 13C) in CDCl3
using TMS as an internal standard. The Fourier Transform Infrared
Spectroscopy (FT-IR) spectra were obtained using a spectropho-
tometer IR-Prestige-21 (Shimadzu). HR-MS spectra were obtained
on a Shimadzu LC–MS-IT-TOF. Thin-layer chromatography was
performed on 0.25 mm plates for TLC silica gel Kieselgel 60 (What-
man) and spots were visualized with short wavelength UV light
254 nm.
2.1.1. Synthesis of methyl salicylate acrylic ester (4)
In a 125 mL ﬂask, 40 mmol (6.08 g) of methyl salicylate (3) was
dissolved in 20 mL of dichloromethane. Then, it was added
42 mmol of triethylamine. The resulting mixture was kept stirring
for 15 min in an ice bath, shortly after this time was dripped into
the ﬂask a solution containing 42 mmol (3.5 mL) of acryloyl chlo-
ride in 10 mL of dichloromethane. The reaction mixture was kept
under agitation and product formation was accompanied by TLC
analysis using ethyl acetate/hexane (1:9 by volume). After 2 h of
reaction, the mixture was put into a separation funnel washed with
a 10% NH4Cl solution (30 mL) to remove the triethylammonium
salt and then preceded to the extraction with dichloromethane
(3  15 mL). The organic phase was then dried with anhydrous
Na2SO4 and the solvent was evaporated under reduced pressure
in rotaevaporatory. The reaction product was isolated by ﬂash
chromatography column on silica gel, using hexane as eluent
(200 mL), and increasing slowly the polarity of eluent. The frac-
tions were collected, and the product was obtained in the form
of oil in 71% yield; yellow oil; IR (KBr): 2999, 2953, 1726, 1631,
1606, 1452, 1404, 1300, 1205, 1153, 1083, 756 cm1; 1H NMR
(300 MHz, CDCl3) d 3.82 (s, 3H), 6.02 (dd, 1H, J = 1.8/10.2 Hz),
6.35 (dd, 1H, J = 10.2/17.2 Hz), 6.61 (dd, 1H, J = 1.8/17.2 Hz), 7.11
(dd, 1H, J = 1.0/8.0 Hz), 7,29 (dt, 1H, J = 1.2/7.6 Hz) 7.54 (dt, 1H,
J = 1.8/7.6 Hz/8.0 Hz) 8.00 (dd, 1H, J = 1.6/7.8 Hz); 13C NMR (CDCl3,
75 MHz) d 52.1; 123.2; 123.7; 126.0; 127.6; 131.7; 132.7; 133.8;
150.3; 164.6; 164.8. HR-MS-Mass calculated: 229.0477 [M+23],
found: 229.0417; C12H13NNa O6.
2.1.2. General protocols for the 1a–1g MBHA preparations
Reactions were carried out using the corresponding 5a–5h
(Fig. 2) aldehydes (1 mmol), the acrylate 4 (x mmol, Table 1),
solvent-free condition or 1.0 mL of protic/nonprotic solvent
(Table 1), 1 or 0.3 mmol of DABCO at 0 or 25 C (Table 1) for
x min h1 day1 (Table 1). After that, the reaction media was di-
rectly ﬁltered through silica gel, using ethyl acetate/hexane (2:8;
3:7 or 4:6) as eluent and the reaction products were concentratedunder reduced pressure. After puriﬁcation by ﬂash chromatogra-
phy using ethyl acetate/hexane (1:9; 2:8 or 3:7) as eluent, the
products were ready for in vitro bioevaluations.
2.1.2.1. Methyl-2-{2-[hydroxy(4-nitrophenyl)methyl])acryloyl-
oxy}benzoate (1a). Seventy-one % yield; yellow oil; IR (KBr):
3478, 3001,2954, 1732, 1612, 1531, 1446, 1400, 1346, 972, 852,
825, 756, 732 cm1; 1H NMR (300 MHz, CDCl3) d 33.76 (s, 3H),
4.06 (d, 1H, J = 4.0 Hz, CHOH), 5.79 (d, 1H, J = 3.6 Hz), 5.96 (s,
1H), 6.65 (s, 1H), 7.04 (dd, 1H, J = 0.8 Hz/8.0 Hz), 7.31 (ddd, 1H,
J = 1.0 Hz/7.8 Hz), 7.54 (ddd, 1H, J = 1.8 Hz/7.6 Hz/7.9 Hz), 7.63 (d,
2H, J = 8.8 Hz) 8.01 (dd, 1H, J = 1.8 Hz/7.8 Hz) 8.19 (d, 2H,
J = 8.8 Hz); 13C NMR (CDCl3, 50 MHz) d 52.3; 71.9, 122.4, 123.4
(2C), 123.6, 126.3; 127.5(2C), 129.5, 131.8, 134.1, 140.9, 147.2,
148.5, 145.0, 164.2, 164.7. HR-MS-Mass calculated: 380.0746
[M+23], found: 380.0701; C18H15NNaO7.
2.1.2.2. Methyl 2-{2-[hydroxy(3-nitrophenyl)methyl])acryloyl-
oxy}benzoate (1b). Seventy % yield; oil; IR (KBr): 3498, 3078,
3020, 2951, 1728, 1608, 1531, 1435, 1350, 1300, 1083, 806, 759,
690 cm1; 1H NMR (300 MHz, CDCl3) d 3.80 (s, 3H), 5.82 (d, 1H,
J = 5.4 Hz), 5.97 (s, 1H), 6.69 (s, 1H), 7.07 (dd, 1H, J = 1.2/8.0 Hz),
7.33 (ddd, 1H, J = 1.2/7.6/7.8 Hz), 7.54 (t, 1H, J = 7.8/8.0 Hz), 7.57
(ddd, 1H, J = 1.8/2.0/7.8 Hz), 7.83 (d, 1H, J = 7.8 Hz), 8.04 (dd, 1H,
J = 1.6 Hz/7.8 Hz), 8.16 (ddd, 1H, J = 0.8/1.2/2.2/7.8 Hz), 8.35 (sl,
1H).; 13C NMR (CDCl3, 7 MHz) d 52.4, 72.1, 121.7, 122.6, 122.7,
123.7, 126.4, 129.3, 129.7, 131.9, 132.9, 134.1, 141.0, 143.4,
148.3, 150.1, 164.4, 164.8, HR-MS-Mass calculated: 380.0746
[M+23], found: 380.0692; C18H15NNaO7.
2.1.2.3. Methyl 2-{2-[hydroxy(2-nitrophenyl)methyl])acryloyl
oxy}benzoate (1c). Seventy-four % yield; oil; IR (KBr): 3479,
3078, 3001, 2954, 1732, 1612, 1531, 1446, 1350, 1300, 1087,
856, 736 cm1; 1H NMR (400 MHz, CDCl3) d 3.85 (s, 3H), 5.66 (s,
1H), 6.44 (s, 1H), 6.56 (s, 1H), 7.17 (dd, 1H, J = 0.8/1.2/8.0 Hz),
7.35 (ddd, 1H, J = 0.8/1.2/8.0 Hz), 7.50 (ddd, 1H, J = 1.2/1.6/
8.0 Hz), 7.59 (ddd, 1H, J = 1.6/8.0 Hz), 7.71 (ddd, 1H, J = 1.2/
7.6 Hz), 8.00 (d, 1H, J = 8.0 Hz), 8.03 (dd, 1H, J = 1.2/8.8 Hz), 8.05
(dd, 1H, J = 1.6/8.0 Hz); 13C NMR (CDCl3, 100 MHz) d 52.5, 67.7,
122.7, 124.0, 124.8, 126.3, 128.4, 128.7, 129.3, 132.0, 133.7,
134.1, 136.1, 141.2, 145.0, 150.4, 164.5, 165.1. HR-MS-Mass calcu-
lated: 380.0746 [M+23], found: 380.0675; C18H15NNaO7.
2.1.2.4. Methyl 2-{2-[hydroxy(pyridin-4-yl)methyl]acryloyl-
oxy})benzoate (1d). Sixty-seven % yield; oil; IR (KBr): 3113,
2951, 2850, 1728, 1708, 1600, 1454, 1296, 1199, 1130, 1056,
968. cm1; 1H NMR (300 MHz, CDCl3) d 3.74 (s, 3H); 5.68 (s, 1H);
5.99 (s, 1H); 6.64 (s, 1H); 7.01 (dd, 1H, J = 1.0/8.2 Hz); 7.30 (ddd,
1H, J = 1.2/7.4/7.8 Hz); 7.38 (dd, 2H, J = 1.0/4.8 Hz); 7.53 (ddd, 1H,
J = 1.4/1.6/8.0 Hz); 8.01 (dd, 1H, J = 1.6/8.0 Hz); 8.52 (dd, 2H,
J = 1.4/4.4 Hz).; 13C NMR (CDCl3, 75 MHz) d 52.3, 71.7, 121.6 (2C),
122.7, 123.6, 126.3, 129.6, 131.9, 134.0, 140.9, 149.6 (2C), 150.0,
Table 1
Different experimental protocols and results in the preparation of 1a–1g compounds (see Scheme 6)
Entry Compd Solvent DABCO (equiv) Temp (C) Time Yielda (%)
1 1a Solvent-free condition 1 0 3 h 27
2 1b Solvent-free condition 1 0 3 h 15
3 1c Solvent-free condition 1 0 6 h 26
4 1a tBuOH/H2Ob 1 25 30 min 8c
5 1a Methanol 1 25 30 min 0d
6 1a Methyl salicylate 1 0 24 h 53
7 1b Methyl salicylate 1 0 48 h 48
8 1c Methyl salicylate 1 0 24 h 51
9 1a Acryloyl salicylate (20 equiv) 0.3 0 3 h 70e
10 1b Acryloyl salicylate (20 equiv) 0.3 0 24 61
11 1c Acryloyl salicylate (20 equiv) 0.3 0 15 0
12 1c Acryloyl Salicylate (20 equiv), methyl salicylate 0.3 0 48 74e
13 1d CH2Cl2 0.3 0 20 min 67
14 1e CH2Cl2 0.3 0 3 h 60
15 1f Solvent-free condition 1 0 4 h 52
16 1g Acetonitrile 1 0 24 h 65
a Puriﬁed yields.
b 9:1 t-BuOH/water.
c After 30 min a large amount of the acrylate 4 was transformed in the methyl salicylate (3).
d After 30 min the acrylate 4 was converted on the methyl acrylate (transesteriﬁcations reaction).
e Acryloyl salicylate (4) and methyl salicylate (3) excess could be easily recovery in high yields (>95%) by a simple ﬁltration.
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found: 336.0814; C17H15NNaO5.
2.1.2.5. Methyl 2-{2-[hydroxy(pyridin-3-yl)methyl]acryloyl-
oxy})benzoate (1e). Sixty % yield; oil; IR (KBr): 3151, 3055,
1728, 1608, 1454, 1431, 1203, 1053, 964, 732 cm1; 1H NMR
(300 MHz, CDCl3) d 3.68 (s, 3H); 5.74 (s, 1H); 6.20 (s, 1H); 6.67
(s, 1H); 7.00 (d, 1H, J = 8.0 Hz); 7.24 (d, 1H, J = 7.8 Hz,); 7.28 (ddd,
1H, J = 1,0/7.8 Hz); 7.51 (ddd 1H, J = 1,8/7.8 Hz); 7.81 (dd, 1H,
J = 7.8 Hz); 7.98 (dd, 1H, J = 1.6/7.8 Hz); 8.39 (d, 1H, J = 4.6 Hz);
8.56 (d, 1H, J = 1.8 Hz).; 13C NMR (CDCl3, 75 MHz) d 51.9, 69.9,
122.8, 123.3, 123.5, 126.0, 128.0, 131.6, 133.8, 134.9, 137.6,
141.5, 148.2 (2C), 149.9, 164.1, 164.7. HR-MS-Mass calculated:
336.0848 [M+23], found: 336.0791; C17H15NNaO5.
2.1.2.6. Methyl 2-{2-[(4-bromophenyl-hydroxy)methyl]acryloyl
oxy}benzoate (1f). Fifty-two % yield; oil; IR (KBr): 3502,
3078, 3001, 2951, 1716, 1604, 1485, 1435, 1404, 1300, 1041,
960, 844, 810, 756, 729 cm1; 1H NMR (300 MHz, CDCl3) d 3.76
(s, 3H); 5.68 (s, 1H); 5.92 (s, 1H); 6.61 (s, 1H); 7.05 (dd, 1H,
J = 1.2/8.0 Hz); 7.31 (1H) 7.33 (d, 2H, J = 8.6 Hz); 7.48 (d, 2H,
J = 8.0 Hz); 7.55 (ddd, 1H, J = 1.6/7.6 Hz); 8.02 (dd, 1H, J = 1.8/
7.8 Hz); 13C NMR (CDCl3, 75 MHz) d 52.3, 72.3, 121.7, 122.8,
123.7, 126.3, 128.5 (2C), 128.8, 131.4 (2C), 131.8, 134.1, 140.1,
141.6, 150.1, 164.6, 164.8. HR-MS-Mass calculated: 390.0103 [M],
found: 390.0138; C18H15BrO5.
2.1.2.7. Methyl 2-{2-[hydroxy(naphthalen-2-yl)methy])acryloyl
loxy}benzoate (1g). Sixty-ﬁve % yield; oil; IR (KBr): 3498,
3055, 2951, 1732, 1604, 1485, 1446, 1300, 1087, 1041, 960, 856,
817, 752 cm1; 1H NMR (300 MHz, CDCl3) d 3.69 (s, 3H); 5.90 (sl,
1H); 5.97 (s, 1H); 6.64 (s, 1H); 7.02 (dd, 1H, J = 0.8/8.0 Hz); 7.28
(ddd, 1H, J = 0.8/7.8 Hz); 7.50 (m, 4H); 7.84 (m, 3H); 7.95 (sl,
1H); 8.01 (dd, 1H, J = 1.6/7.8 Hz); 13C NMR (CDCl3, 75 MHz) d
52.3, 72.8, 123.0, 123.8, 124.8, 125.8, 126.0, 126.2, 126.2, 127.7,
128.1, 128.2, 128.8, 131.9, 133.1, 133.3, 133.9, 138.4, 142.0,
150.2, 164.8, 165.0 HR-MS-Mass calculated: 385,1052 [M+23],
found: 385.0976; C17H15NNaO5.
2.1.2.8. Bis(2-(methoxycarbonyl)phenyl)-2-methylenepentane
dioate (25). Fifty-one % yield; oil; IR (KBr): 2999, 2953,
1726, 1631, 1606, 1452, 1404, 1300, 1205, 1153, 1083, 756. cm
1; 1H NMR (300 MHz, CDCl3) d 2.96 (m, 4H), 3.84 (sl, 3H), 3.85(sl, 3H), 5.94 (s, 1H), 6,54 (s, 1H), 7,10 (dd, 1H, J = 1.0 Hz/8,0 Hz),
7,17 (dd, 1H, J = 1.0 Hz/8,0 Hz), 7,32 (m, 1H), 7,56 (m, 1H), 8.05
(m, 1H); 13C NMR (CDCl3, 75 MHz) d 27.1, 32.8, 52.2 (2C), 123.2 e
123.4 (2C), 123.8 (2C), 126.0 (2C), 128.2, 131.7, 131.8, 133.81
(2C), 138.1, 150.6 (2C), 165.0 (2C), 165.3, 171.4 HR-MS-Mass calcu-
lated: 435.1056 [M+23], found: 435.0965; C22H20O8.
2.2. Biology33
Logarithmic phase promastigotes (1  106 parasites mL1) of
L. amazonensis (MHOM/IFLA/BR/67/PH8) and L. chagasi (MCAN/
BR/99/JP15) were incubated at 26 C in Schneider’s Drosophila
medium supplemented with 20% of fetal bovine serum, streptomy-
cin (100 lg mL1), and penicillin (100 U mL1), in the presence or
absence of different concentrations of new hybrids chalcones-like
1a–1g MBHA, methyl salicylate acrylic ester (4), methyl salicylate
(3) and methyl salicylate acrylic ester dimer 6 The reference drugs
Glucantime and Amphotericin Bwere used as control. After 72 h,
parasites were collected, ﬁxed in isotonic solution (10.5 g citric
acid, 7.0 g NaCl, 5.0 mL formalin and 1000 mL distilled water)
and examined under light microscopy. The inhibitory effect of
the compounds on cell growth was estimated by cell counting
using a Neubauer chamber. The IC50/72 h, concentration responsi-
ble for a 50% reduction in culture growth after 72-hour incubation
was determined by the probity regression model using the soft-
ware SPSS 8.0 for Windows. All experiments were performed in
triplicate and repeated at least three times. Statistical analysis of
data was done by means of one-way ANOVA. P values of 0.05 or
less were considered signiﬁcant.
3. Results and discussion
3.1. Chemistry
We chose as strategy the use of MBHR44 between the unpub-
lished acrylate 4 (Scheme 3) and the commercials aldehydes
5a–5h (Fig. 2) as key-step of the MBHA 1a–1g one-pot syntheses.
The synthesis of 4was carried out in good yield reacting methyl
salicylate (3) and commercial acryloyl chloride on CH2Cl2 as sol-
vent at 0 C for 2 h (71%, Scheme 3). The acrylate 4 is stable for
more than 30 days at low temperature (4 C/20 C) or stable
at room temperature by addition of BHT as antipolymerization.
However, a new acrylate 6 was formed after 48 h at room
DABCO
(0.3 or 1 Equiv.)
1a-1g4
5a-5e ,
5g, 5h
OO
O
O O
Ar+
OO
O
O OH
Ar
Condition
(solvent, solvent-free, 
temperature, rate)(1-20 Equiv.)
Scheme 6. Morita–Baylis–Hillman reaction on the 1a–1g preparations (see Table
1).
CO2CH3
O
O
O
O
CO2CH3
6
48h, r.t.
solvent-free
51%
O
O
CO2CH3
4
2
Dimerization
Scheme 4. Spontaneous dimerization of acrylate 4. Synthesis of acrylate 6.
O
O
CO2CH3
OH
O
CO2CH3
+
Cl TEA, CH2Cl2
0 oC, 2h, 71%
43
Scheme 3. Synthesis of acrylate 4.
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ization reaction (Scheme 4).
Our ﬁrst protocol aim to prepare 1a–1g MBHA was at low tem-
perature and on solvent-free condition.35 When the reaction be-
tween excess of acrylate 4 and aldehyde 5a was performed under
1 equiv of DABCO as promoter, the expected adduct 1a was ob-
tained in low yield (Table 1, entry 1) and the principal product of
reaction was the dioxanone 7 (Scheme 5), that can be understood
based on nonprotic mechanism proposed by McQuade.45 When
the reactions were carried out with aldehydes 5b and 5c (on the
same conditions) the 1b and 1c adducts were obtained in low
yields and over again the corresponding dioxanones were obtained
as principal products (Table 1, entries 2 and 3, see also Scheme 6).
Aiming to minimize the dioxanones formation, the MBHR with
aldehyde 5a was carried out in the presence of protic t-butanol/
water (9:1) as solvent, modifying the nonprotic to protic mecha-
nism, as proposed by Aggarwal.46 Both, protic and the nonprotic
mechanisms to the MBHR were recently corroborated by Coelho.47
As expected, there was a total disappearance of 7. Unfortunately,
due the salicylate moiety on MBHA 1a to be a good leaving group,
the adduct 1a was also obtained in low yield, and the methyl salic-
ylate (3) was the principal compound obtained of this reaction
(Table 1, entry 4). The use of anhydrous methanol as solvent
presented to be also inefﬁcient producing the methyl acrylate from
a transesteriﬁcation reaction (Table 1, entry 5). However, when the
methyl salicylate itself was used as protic solvent, the 1a, 1b, and
1c MBHA could be obtained in moderated yields (Table 1, entries
6, 7, and 8).
As reported by McQuade, excess of aldehydes under a pro-
longed reaction time leads to the formation of dioxanones like
7.48 Therefore, we realize to used a larger amount of acrylate 4
(20 equiv) aim to minimize the formation of dioxanones. Besides
that, in diluted reaction medium, the formation of dioxanones
would be less favored, after the proton transfer step (rate-
determining step, RDS). We also decrease the DABCO quantity toDABCO 
(1Equiv.)
no solvent
 0 ºC
2 mmol 1 mmol
4 5a
OO
O
O O
NO2
+
O
Scheme 5. Dioxanone 7 as the principal product0.3 equiv trying to minimize the dimers formation between the
acrylates. Satisfactorily, this experimental modiﬁcation was efﬁ-
cient and we could to prepare the 1a and 1b MBHA in good yields
(Table 1, entries 9 and 10). Curiously, MBHA 1c could not be pre-
pared using this methodology even after ﬁfteen days of reaction
(Table 1, entry 11). Fortunately, in this case, the addition of methyl
salicylate (3) as protic solvent and using 20 equiv of 4was efﬁcient
for the MBHA 1c preparation in good yield (Table 1, entry 12). The
acrylate 4 could be easily recovery in high yields (>95%) by a sim-
ple ﬁltration. These efﬁcient results can be understood based on
the very recent Cantillo and Kappe work.49 They proven that the
use of phenols as a solvent or an addictive can improve rate and
yields on MBH reaction by change it slow determination rate
(RDS).49
For the preparation of the 1d and 1e pyridine MBHA derivatives,
reaction were carried out between the aldehydes pyridine-4-car-
boxaldehyde (5d) or pyridine-3-carboxaldehyde (5e) with the
acrylate 4, on dichloromethane as solvent. In these cases, the reac-
tions mixtures showed low solubilities in solvent-free conditions.
Dichloromethane also has the advantage being easily evaporated
and do not contained signiﬁcant traces of water, which could
hydrolyze the MBHA. These experimental protocols produced 1d
and 1e in moderated or good yields (Table 1, entries 13 and 14).
Unlike of the expected, reaction between pyridine-2-carboxal-
dehyde (5f) and acrylate 4 produced several byproducts and the
corresponding chalcone-like compound could not be isolated (not
shown). Based on characteristics fragmentation obtained by
CGMS, we speculate that principal byproducts is the indolizine
8 (m/z = 295, m/z = 264, m/z = 144 and m/z = 116, Scheme 7).
Unfortunately due to the existence of several byproducts of similar
polarities of 8, we cannot isolate pure indolizine 8 and than its
complete characterization was not done. Basavaiah et al. estab-
lished that several indolizines can be synthesized from MBHR.50
Several conditions (not shown) were investigated aiming to pre-
pare 8 efﬁciently, but without any success.
For the adduct 1f preparation (Fig. 1) was used solvent-free con-
dition at 0 C (Table 1, entry 15, and 52% yield). Unfortunately, the
use of other protocols not improved yield on 1f preparations. Final-
ly, we prepared, in improved possible way, the MBHA 1g in mod-
erated yield (65% yields, Table 1, entry 16) by use acetonitrile as
solvent. Curiously, in this last case the solvent-free condition, prot-
ic and phenol addition as solvent not improved yields.+
27% >50%
71a
O
O
O OH
NO2
O O
O
NO2
NO2
of MBH reaction on solvent-free condition.
OO
CO2CH3
8
N
O
O
CO2CH3
N
 C17H13NO4
m/z: 295
O
O
N
O
 C16H10NO3
m/z: 264
N N
O
 C9H6NO
m/z: 144
 C8H7N
m/z: 116
Scheme 7. Characteristics fragmentation of 8.
Figure 3. Conformationals minima of 1a and 1c, calculated by B3LYP/6-311++G
(d,p) as calculation level from GAUSSIAN 09 (versions for Linux).
Table 2
a,b Antileishmanial in vitro activity of 3, 1a–1g, 4 and dimer 6 and Glucantime as
reference compound
Compd IC50
(lg mL1) L.
amazonensis
IC50 (lM) L.
amazonensis
IC50
(lg mL1)
L. chagasi
IC50 (lM)
L. chagasi
3 34.73 228.49 39.74 261.45
1a 4.05 11.34 20.48 57.34
1b 8.16 22.86 14.51 40.64
1c 2.73 7.65 3.62 10.14
1d 7.46 23.83 10.44 33.35
1e 9.75 31.15 12.11 38.69
1f 8.58 22.00 16.78 43.03
1g 3.26 9.00 14.98 41.38
4 22.35 108.50 24.48 118.83
6 9.25 22.45 20.22 49.08
Glucantime >4000 Variable >4000 Variable
Amphotericin B 0.11 0.12 0.64 0.69
a IC50 values obtained from a minimum of three separate experiments performed
in triplicate are shown.
b The reference drugs Glucantime and Amphotericin B were used in this study
and in vitro activities.
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Our biological data are described in Table 2 and a few comments
about these results deserve be made. Initially, the IC50 evaluation of
methyl salicylate (3) and acryloyl salicylate (4) on L. amazonensis
and L. chagasi have shown a moderated antipromastigote activities
(Table 2) when compared to the designed new compounds 1a–1g.
Secondly, we can note that the new hybrids 1a–1g have higher tox-
icity on L. amazonensis than on L. chagasi. Additionally, the leish-
manicidal activities of compounds 2a–2g (IC50 = 50.08–731.37 lM
on L. amazonensis and IC50 = 52.92–724.59 lM on L. chagasi) pre-
sented in our previous article.33 are much smaller than the hybrids
1a–1g of this new series of chalcones-like compounds (Table 2).
This experimental observation conﬁrmed the importance of the
salicylate moiety in 1a–1g, to increase the leishmanicidal activity
of this new series, may be also a consequence of anti-COXs activity,
the best known mechanism of action to salicylate deriva-
tives.17,18,21,51 Thus, as idealized by us, the molecular hybridization
is critical to increase the leishmanicidal activity.
We can also notice in Table 2 that the ortho nitro compound 1c
presents the most leishmanicidal activity on both L. amazonensis
and L. chagasi in the 1a–1g series. We recently described that the
presence of the ortho nitro group also increases antileishmania
activity being the compound 2c (Fig. 1) the most active in the
2a–2g series.35 We can identify on geometric shapes of the 1a
and 1c calculated conformationals minima (Fig. 3) that, differentfrom that occurs on compound 1a, the NO2 group in 1c is not com-
pletely conjugated with the aromatic moiety. This conformational
modiﬁcation caused by the o-nitro group can change the interac-
tion between ligand–enzyme or/and change the reduction poten-
tial of these compounds modifying, for example, the redox
system TR/trypanothione that is vital for parasite survival within
the host cell.52–54 Even if, up to now, the correct biological mecha-
nism of action of these MBHA is not known, it is reasonable to
speculate for these different biological activities on 1a, 1b, and
1c compounds in this series.
Further, the position 4 or 3 of the nitrogen atom in the pyridine
rings into the corresponding 1d and 1e compounds did not signif-
icantly alter these bioactivities (Table 2). The same tendency was
observed in the previous studied 2a–2g series,35 (IC50 = 488.98 lM
on L. amazonensis; IC50 = 494.81 lM on L. chagasi to the compound
2d and IC50 = 448.50 lM on L. amazonensis; IC50 = 350.57 lM on L.
chagasi to the compound 2e).35 However, the 1d and 1e (Table 2)
were almost 20 times more active than the corresponding com-
pounds 2d and 2e.
The antileishmania activity of compound 1f is similar than 1d
and 1e (Table 2), differently that determinate to 2f,35 which is al-
most 5 times more active than the corresponding compounds 2d
and 2e in the 2a–2g series (shown in the previous paragraph).
It should be noted that the dimer 6 (Scheme 4), which also is an
analogues of chalcones, has a signiﬁcant activity against the L.
amazonensis and L. chagasi, unlike the corresponding monomer 4.
This remark suggests once again the importance of the presence
of two the aromatic groups in the 1a–1g series, one of the
4256 T. P. Barbosa et al. / Bioorg. Med. Chem. 19 (2011) 4250–4256characteristics of chalcones. Finally, compound 1g is a second more
active in this new series (Table 2) of hybrid compounds. It is rea-
sonable to propose in this case that, since compound 1g is the most
lipophilic into this new series (calculated from Pharma-algo-
rithms, Log P = 4.54 ± 0.51),55 lipophilicity it could be an impor-
tant parameter for it bioactivity.4. Conclusion
In this work, we successfully applied the current mechanistic
knowledge of MBHR, to improve synthetic results.45–49 Our data
also are useful to corroborate these mechanistic proposals for this
ﬁne reaction.
Moreover, in this work, we idealized, synthesized and show
with success one more example of molecular hybridization, a very
important strategy in Medicinal Chemistry.36
Seven new chalcone-like compounds 1a–1g were designed
using molecular hybridization strategy, efﬁciently synthesized,
completely characterized and bioevaluated as a new series of
in vitro leishmanicides. Amphotericin B presented a higher
in vitro activity compared with compounds 1a–1g and 2a–2g.
However, Amphotericin B is well-known for its severe and poten-
tially lethal side effects and very high cost to production.56 In addi-
tion, preparation of 1a–1g have advantages in terms of yield and
operational simplicity.
Finally, all these new original series of compounds 1a–1g were
active against the promastigotes form of L. amazonensis and
L. chagasi and much more active than the previous bioevaluated
series 2a–2g.35 This prospective work needed to study the real
mechanism of action of these new compounds. Then, the study
of toxicities in macrophages and the biological mechanisms of
action of these new compounds will now be investigated.Acknowledgments
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